ImExHS And 2 Australian AI Stocks To Watch

AI related investment is now a key pillar of US economic growth, which shows how quickly this technology can reshape entire sectors. Healthcare is one of the clearest beneficiaries, as algorithms help doctors read scans, personalise treatments and cut hospital paperwork. For Australian investors, that points to a growing opportunity. This article walks through three AI focused healthcare stocks from our screener that aim to tap into that trend.

The three stocks covered below are just a small sample from this AI in healthcare theme, and the full screen surfaced 4 more companies with equally compelling narratives that are not included in this article. To see the wider field and sort through it on your terms, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener to identify, compare, and analyze the highest conviction ideas from this list.

ImExHS (ASX:IME)

Overview: ImExHS is a Sydney based healthtech company that sells cloud medical imaging software and AI ready radiology data for diagnostics.

Operations: The business generates about A$10 million from software and A$21 million from radiology services, almost entirely in Latin America.

Market Cap: A$18 million

ImExHS matters for this AI healthcare screen because its AQUILA platform and radiology services give it both the software and real clinical data pipes that AI depends on to read scans remotely and support doctors’ decisions at scale.

"They also understand the challenge now is to drive the software sales and revenue much faster in 2026."

What happens to ImExHS’s margins and growth ambitions if one unseen pressure on that software centric shift does not break their way?

If that pressure matters to your thesis, read the full narrative for ImExHS to see how ImExHS could accelerate or stall as AI radiology adoption shifts.

Paragon Care (ASX:PGC)

Overview: Paragon Care supplies hospitals and clinics with medical equipment, consumables, and AI-enabled imaging and software that support diagnostic workflows.

Operations: The business reports about A$3.5b from ANZ operations and A$160 million from Asia, with most sales in Australia and New Zealand.

Market Cap: A$257 million

Paragon Care plugs into the AI healthcare theme through the imaging suites and software it distributes, where machine learning tools are starting to influence how quickly clinicians read scans and organise care for patients across its hospital and clinic customer base.

"The integration of recent acquisitions and ongoing operational synergies (with a target of $12 million annual run-rate in FY '26), coupled with the consolidation of business functions onto a unified JDE platform, are likely to improve cost efficiencies and structurally enhance net margins and EBITDA."

What matters now is how one quiet shift in where AI-ready products sit in the sales mix eventually shapes those margins.

If that shift in AI product mix is what you are watching, read the full narrative for Paragon Care to see whether Paragon Care’s margins could quietly accelerate or stall.

Artrya (ASX:AYA)

Overview: Artrya develops the Salix cloud-based AI imaging platform that helps clinicians detect and manage coronary artery disease from CCTA scans.

Operations: The business currently reports about A$0.03 million in revenue from development of its AI-driven CCTA image analysis technology in Australia.

Market Cap: A$432 million

Artrya matters for this AI healthcare screen because Salix targets one of medicine’s biggest killers, heart disease, with algorithmic support for earlier, more precise intervention.

"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."

What happens to Artrya’s earnings power if one key assumption about how quickly hospitals shift their coronary imaging workflows does not hold?

That adoption question is exactly what the full narrative for Artrya unpacks, including how Artrya’s CCTA volume path could accelerate or stall as workflows shift.

Seeking Fresh Alternatives Before They Fly

Fresh ideas move first. Late money chases. Use these curated lists to spot potential breakout momentum while it is still under the radar for now. Act now.

• Hunt for smaller companies where strong balance sheets support momentum by using the list of solid balance sheet and fundamentals (12 results) before those stories are fully caught by the crowd.
• Ride growing interest in quantum technology by scanning the curated 25 quantum computing stocks that gathers listed players pushing real progress while attention is still dropping elsewhere.
• Target potential income resilience by reviewing hand picked 4 dividend fortresses before yield hunters narrow the window on these payout opportunities.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com